In serous endometrial carcinoma, the most aggressive from of this cancer, CHD4 mutations are most frequent and occur alongside mutations in tumour suppressor or oncogenes including TP53, PIC3CA, PPP2R1A or FBXW76. This evidence concerns the gene TP53 and cancer.